Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

508

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Interventions

DRUG: Solriamfetol 150 MG
DRUG: Placebo

Sponsor

Axsome Therapeutics, Inc.